



Contact Information:

Ralph Barry, Chief Business Officer
Aegis Therapeutics LLC
1-858-618-1400 Ext. 102
Email: rbarry@aegisthera.com

Aegis Therapeutics to Present at the 4th Annual Peptide Therapeutics Symposium, November 17 – 18, 2009

SAN DIEGO, CA September 15, 2009/ NewsWire Today/ -- In a talk entitled: "Non-Invasive Systemic Delivery of Peptides with High Bioavailability", Dr. Edward Maggio, CEO of Aegis Therapeutics will present recent developments in highly efficient systemic delivery of peptide therapeutics through various transmucosal routes including oral, nasal, and buccal/sublingual administration, at the 4th Annual Peptide Therapeutics Symposium to be held at The Salk Institute for Biological Sciences, San Diego, on November 17 – 18, 2009.

The symposium, sponsored by the Peptide Therapeutics Foundation, brings together world leaders in peptide research from academia and the biopharmaceutical industry and will present the most recent and exciting developments in the peptide field. The scientific program will focus on novel peptide strategies to address cell surface and intracellular targets, and non-parenteral peptide drug delivery. The keynote address will be given this year by Professor Roger Tsien, 2008 Nobel Laureate for Chemistry. The full program for the meeting may be viewed at www.peptidetherapeutics.org.

About Aegis Therapeutics

Aegis Therapeutics LLC is a drug delivery technology company commercializing its patented drug delivery and drug formulation technologies through product-specific licenses. Our patented Intravail[®] drug delivery technology enables the non-invasive delivery of a broad range of protein, peptide and non-peptide macromolecular therapeutics via the intranasal administration route with exceptionally high and unmatched bioavailability that can currently only be achieved by injection. Intravail[®] has also been successfully applied to buccal, oral, and rectal administration of both small molecule and peptidic drugs. Our patented ProTek[®] technology allows creation of proprietary, easily manufacturable, and stable aqueous or lyophilized dosage forms that maintain the integrity and physiological activity of many protein and peptide therapeutics. ProTek[®] technology is applicable to injectable, intranasal, and other dosage forms. For more information about Aegis, please visit the Aegis website at: www.aegisthera.com.

###